Ironwood Pharmaceuticals (IRWD) Price to Sales (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Price to Sales across 17 years of filings, most recently posting 6.15 for Q2 2026.

• In Q2 2026, Price to Sales rose 348.53% year-over-year to 6.15; the TTM figure through Jun 2026 stood at 1.79 (up 371.38% YoY), while the FY2025 annual figure was 1.86, down 8.13% from the prior year.
• Price to Sales came in at 6.15 for Q2 2026 at Ironwood Pharmaceuticals, up from 5.42 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 20.01 in Q1 2022 to a low of 1.37 in Q2 2025.
• Average Price to Sales over 5 years is 11.49, with a median of 12.37 recorded in 2023.
• Year-over-year, Price to Sales slumped 87.56% in 2025 and jumped 348.53% in 2026.
• Over 5 years, Price to Sales stood at 17.8 in 2022, then declined by 14.53% to 15.22 in 2023, then plunged by 48.49% to 7.84 in 2024, then surged by 46.94% to 11.52 in 2025, then slumped by 46.57% to 6.15 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 6.15 in Q2 2026, 5.42 in Q1 2026, and 11.52 in Q4 2025.